Nomogram Based on Inflammatory Biomarkers and Nutritional Indicators for Predicting Overall Survival in Locoregionally Advanced Nasopharyngeal Carcinoma

References

• Chen Y-P, Chan ATC, Le Q-T, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. doi:10.1016/s0140-6736(19)30956-0
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Mao YP, Xie FY, Liu LZ, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol. 2009;73(5):1326–1334. doi:10.1016/j.ijrobp.2008.07.062
   PubMed Web of Science ®Google Scholar
• Wei KR, Zheng RS, Zhang SW, Liang ZH, Ou ZX, Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China in 2010. Chin J Cancer. 2014;33(8):381–387. doi:10.5732/cjc.014.10086
   PubMedGoogle Scholar
• Zhang MX, Li J, Shen GP, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer. 2015;51(17):2587–2595. doi:10.1016/j.ejca.2015.08.006
   PubMed Web of Science ®Google Scholar
• Pfister DG, Spencer S, Adelstein D, et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(7):873–898. doi:10.6004/jnccn.2020.0031
   PubMed Web of Science ®Google Scholar
• Tan T, Lim WT, Fong KW, et al. Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: a randomized, Phase 2/3 trial in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015;91(5):952–960. doi:10.1016/j.ijrobp.2015.01.002
   PubMed Web of Science ®Google Scholar
• Chen L, Hu C-S, Chen X-Z, et al. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: long-term results of a Phase 3 multicentre randomised controlled trial. Eur J Cancer. 2017;75:150–158. doi:10.1016/j.ejca.2017.01.002
   PubMed Web of Science ®Google Scholar
• Bullock AF, Greenley SL, McKenzie GAG, Paton LW, Johnson MJ. Relationship between markers of malnutrition and clinical outcomes in older adults with cancer: systematic review, narrative synthesis and meta-analysis. Eur J Clin Nutr. 2020;74(11):1519–1535. doi:10.1038/s41430-020-0629-0
   PubMed Web of Science ®Google Scholar
• Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004;14(6):433–439. doi:10.1016/j.semcancer.2004.06.006
   PubMed Web of Science ®Google Scholar
• Yalcin S, Gumus M, Oksuzoglu B, et al. Nutritional aspect of cancer care in medical oncology patients. Clin Ther. 2019;41(11):2382–2396. doi:10.1016/j.clinthera.2019.09.006
   PubMed Web of Science ®Google Scholar
• Liu D, Czigany Z, Heij LR, et al. The value of platelet-to-lymphocyte ratio as a prognostic marker in cholangiocarcinoma: a systematic review and meta-analysis. Cancers. 2022;14(2):438.
   PubMed Web of Science ®Google Scholar
• Valero C, Lee M, Hoen D, et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 2021;12(1). doi:10.1038/s41467-021-20935-9
   Web of Science ®Google Scholar
• Zhang Q, Song MM, Zhang X, et al. Association of systemic inflammation with survival in patients with cancer cachexia: results from a multicentre cohort study. J Cachexia Sarcopeni. 2021;12(6):1466–1476. doi:10.1002/jcsm.12761
   PubMed Web of Science ®Google Scholar
• Nost TH, Alcala K, Urbarova I, et al. Systemic inflammation markers and cancer incidence in the UK Biobank. Eur J Epidemiol. 2021;36(8):841–848. doi:10.1007/s10654-021-00752-6
   PubMed Web of Science ®Google Scholar
• Kumarasamy C, Tiwary V, Sunil K, et al. Prognostic utility of platelet-lymphocyte ratio, neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in head and neck cancers: a detailed PRISMA compliant systematic review and meta-analysis. Cancers. 2021;13(16):4166. doi:10.3390/cancers13164166
   PubMed Web of Science ®Google Scholar
• Du XJ, Tang LL, Mao YP, et al. Value of the prognostic nutritional index and weight loss in predicting metastasis and long-term mortality in nasopharyngeal carcinoma. J Transl Med. 2015;13(1). doi:10.1186/s12967-015-0729-0
   Web of Science ®Google Scholar
• Peng RR, Liang ZG, Chen KH, Li L, Qu S, Zhu XD. Nomogram based on Lactate Dehydrogenase-to- Albumin Ratio (LAR) and Platelet-to-Lymphocyte Ratio (PLR) for predicting survival in nasopharyngeal carcinoma. J Inflamm Res. 2021;14:4019–4033. doi:10.2147/Jir.S322475
   PubMed Web of Science ®Google Scholar
• Tan LP, Tan GW, Sivanesan VM, et al. Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma. Int J Cancer. 2020;146(8):2336–2347. doi:10.1002/ijc.32656
   PubMed Web of Science ®Google Scholar
• Liu L-T, Chen Q-Y, Tang L-Q, et al. Neoadjuvant or adjuvant chemotherapy plus concurrent CRT versus concurrent CRT alone in the treatment of nasopharyngeal carcinoma: a Study Based on EBV DNA. J Natl Compr Canc Netw. 2019;17(6):703–710. doi:10.6004/jnccn.2018.7270
   PubMed Web of Science ®Google Scholar
• Hui EP, Li WF, Ma BB, et al. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. Ann Oncol. 2020;31(6):769–779. doi:10.1016/j.annonc.2020.03.289
   PubMed Web of Science ®Google Scholar
• Wang W-Y, Twu C-W, Chen -H-H, et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res. 2010;16(3):1016–1024. doi:10.1158/1078-0432.CCR-09-2796
   PubMed Web of Science ®Google Scholar
• Tang L-Q, Li C-F, Li J, et al. Establishment and validation of prognostic nomograms for endemic nasopharyngeal carcinoma. J Natl Cancer Inst. 2016;108(1):djv291. doi:10.1093/jnci/djv291
   PubMedGoogle Scholar
• Guo R, Tang -L-L, Mao Y-P, et al. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. Cancer. 2019;125(1):79–89. doi:10.1002/cncr.31741
   PubMed Web of Science ®Google Scholar
• Lan XW, Xiao Y, Zou XB, Zhang XM, OuYang PY, Xie FY. Outcomes of adding induction chemotherapy to concurrent chemoradiotherapy for stage T3N0-1 nasopharyngeal carcinoma: a propensity-matched study. Onco Targets Ther. 2017;10:3853–3860. doi:10.2147/OTT.S133917
   PubMed Web of Science ®Google Scholar
• Frikha M, Auperin A, Tao Y, et al. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02). Ann Oncol. 2018;29(3):731–736. doi:10.1093/annonc/mdx770
   PubMed Web of Science ®Google Scholar
• Huang WY, Lin CL, Lin CY, et al. Survival outcome of patients with nasopharyngeal carcinoma: a nationwide analysis of 13 407 patients in Taiwan. Clin Otolaryngol. 2015;40(4):327–334. doi:10.1111/coa.12371
   PubMed Web of Science ®Google Scholar
• Xu C, Chen YP, Liu X, et al. Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy. Oral Oncol. 2017;69:99–107. doi:10.1016/j.oraloncology.2017.04.015
   PubMed Web of Science ®Google Scholar
• Chan ATC, Hui EP, Ngan RKC, et al. Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J Clin Oncol. 2018:JCO2018777847. doi:10.1200/JCO.2018.77.7847
   PubMed Web of Science ®Google Scholar
• Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18(3):121–126. doi:10.4103/aam.aam_56_18
   PubMed Web of Science ®Google Scholar
• Riesco A. Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer. 1970;25(1):135–140. doi:10.1002/1097-0142(197001)25:1<135::aid-cncr2820250120>3.0.co;2-9
   PubMed Web of Science ®Google Scholar
• Jiang Y, Qu S, Pan X, Huang S, Zhu X. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in intensity modulated radiation therapy for nasopharyngeal carcinoma. Oncotarget. 2018;9(11):9992–10004. doi:10.18632/oncotarget.24173
   PubMedGoogle Scholar
• Lu A, Li H, Zheng Y, et al. Prognostic significance of neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio, and platelet to lymphocyte ratio in patients with nasopharyngeal carcinoma. Biomed Res Int. 2017;2017:3047802. doi:10.1155/2017/3047802
   PubMed Web of Science ®Google Scholar
• Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69(4):491–497. doi:10.1016/s0149-2918(05)80001-3
   PubMed Web of Science ®Google Scholar